EASL 2019 – Novo buys into Gilead’s Nash combo plan
Today’s deal will see the companies take a triple combination into clinical trials.
Upcoming events – a legal verdict for Enbrel and a clinical one for Cymabay
Amgen awaits a make-or-break US verdict on its best-selling drug, while Cymabay looks for evidence that it could become a Nash contender.
Inventiva’s fibrosis flop hits Nash hopes
A stumble for Inventiva’s lanifibranor in a rare fibrotic disease could bode ill for its prospects in Nash, and for those of other PPAR agonists.
Gilead’s first big Nash bash ends in the trash
The failure of the Stellar-4 study of selonsertib is a big blow for Gilead, but has not dented enthusiasm for other Nash players.
Albireo comes up to IBAT in Nash
Albireo is taking aim at yet another Nash target, but Shire and Glaxosmithkline have already ditched projects with similar mechanisms.
JP Morgan 2019 day three roundup – Abbvie rekindles the takeover flame
Day three of the biotech dog and pony show saw one pharma company that unequivocally wants and needs to buy.
AASLD 2018 – Viking lands blow in early Nash skirmish
Viking’s VK2809 looks at least as good as Madrigal’s MGL-3196 in liver disease – but investors should be careful of making comparisons.
Kickstarting ideas
Independent, data-driven daily news and analysis on pharma, biotech and medtech.